In the last trading session, 1.06 million ORIC Pharmaceuticals Inc (NASDAQ:ORIC) shares changed hands as the company’s beta touched 1.20. With the company’s per share price at $7.68 changed hands at $0.21 or 2.81% during last session, the market valuation stood at $545.49M. ORIC’s last price was a discount, traded about -116.8% off its 52-week high of $16.65. The share price had its 52-week low at $6.33, which suggests the last value was 17.58% up since then.
Analysts gave the ORIC Pharmaceuticals Inc (ORIC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.08. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ORIC as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. ORIC Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.54.
ORIC Pharmaceuticals Inc (NASDAQ:ORIC) trade information
Instantly ORIC was in green as seen at the end of in last trading. With action -7.13%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -4.83%, with the 5-day performance at -7.13% in the red. However, in the 30-day time frame, ORIC Pharmaceuticals Inc (NASDAQ:ORIC) is -22.19% down.
The consensus price target for the stock as assigned by Wall Street analysts is 20, meaning bulls need an upside of 61.6% from its current market value. According to analyst projections, ORIC’s forecast low is 20 with 20 as the target high. To hit the forecast high, the stock’s price needs a -160.42% plunge from its current level, while the stock would need to soar -160.42% for it to hit the projected low.
ORIC Pharmaceuticals Inc (ORIC) estimates and forecasts
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -15.32%. The 2025 estimates are for ORIC Pharmaceuticals Inc earnings to decrease by -13.71%, but the outlook for the next 5-year period is at -9.63% per year.
ORIC Pharmaceuticals Inc (NASDAQ:ORIC)’s Major holders
FMR LLC holds the second largest percentage of outstanding shares, with 7.3057% or 4.92 million shares worth $34.79 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were ACAP Strategic Fund and Vanguard Total Stock Market Index Fund. With 1.92 shares estimated at $14.75 million under it, the former controlled 2.70% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.65% of the shares, roughly 1.88 shares worth around $14.44 million.
